AEZS (Mcap $67M) (Cash $46M) PDUFA Date November 5 ..Next Hot Play guys
This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .
FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !
AEZS could run to $3-5 before FDA decision in early November .GL Aeterna Zentaris (AEZS)
Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD
•Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN™ as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency
. NDA currently undersubstantive review by the US Food and Drug Administration with a Prescription Drug User Fee Act date of November 5,2014
Zoptarelin doxorubicin
Operate trial in support of achieving first interim analysis for ZoptEC Phase 3 trial in H1-2015